复星医药(600196.SH)拟参与投资设立新药创新基金
格隆汇10月16日丨复星医药(600196.SH)公布,2019年10月16日,公司与苏州吴中经济技术开发区(以下简称“吴中经开区”)管理委员会及苏州市吴中金融控股集团有限公司(以下简称“吴中金控”)签订《战略合作框架协议》,就参与投资设立新药创新基金等达成合作意向。
新药创新基金拟由复星医药及/或其控股子公司发起募集设立,首期募集资金规模约人民币10至15亿元。该基金旨在充分利用本集团已有的全球领先大学创投基金网络以及前沿生物技术的丰富资源,通过基金投资+孵化落地的等模式,将海内外优质的人才与技术产品引入国内进行落地。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.